Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
An expert who studies stocks said Structure Therapeutics is doing better than the overall market and kept their belief that the company should be worth $110 per share. This shows the expert still thinks the company is on a good path, even though they didn't change their mind.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.